CPHD : Summary for CEPHEID - Yahoo Finance

U.S. Markets closed

Cepheid (CPHD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
52.950.00 (0.00%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close52.95
Bid0.00 x
Ask0.00 x
Day's Range52.95 - 53.00
52 Week Range25.09 - 53.91
Avg. Volume2,807,760
Market Cap3.88B
PE Ratio (TTM)-102.62
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cepheid (CPHD): What Smart Money Thinks about This Stock?
    Insider Monkey3 days ago

    Cepheid (CPHD): What Smart Money Thinks about This Stock?

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]

  • PR Newswire28 days ago

    Danaher Completes Acquisition Of Cepheid

    WASHINGTON, Nov. 4, 2016 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced that today it completed its acquisition of Cepheid (NASDAQ: CPHD). Copper Merger Sub, Inc. ("Copper"), ...

  • PR Newswirelast month

    30 Minute Or Less Molecular Flu/RSV Test Now Available Outside The US

    Upper respiratory infections are among the most common reasons for outpatient visits in the United States and worldwide.2,3  Early symptoms for a wide variety of viral and bacterial respiratory infections are often clinically indistinguishable, yet treatment is different depending on the cause of infection, highlighting the importance of accurate diagnostic tests like Xpert Xpress Flu/RSV.  With this development, hospitals and clinics can reliably diagnose influenza and respiratory syncytial virus (RSV) infection in 30 minutes or less. Xpert Xpress Flu/RSV is twice as fast as its predecessor, Xpert Flu/RSV XC, but has comparable performance characteristics.  The new assay features a novel design, which employs multiple targets for each virus.  The built-in redundancy provides very high test sensitivity, avoiding the impact of seasonal drift that has been a problem historically with molecular tests, while maintaining high specificity.